bp1001
Nucleic acidexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2010 (NCT01159028)
Timeline
Indications
Studied for
- Carcinoma, Ovarian Epithelial · Phase 1
- Endometrial Neoplasms · Phase 1
- Fallopian Tube Neoplasms · Phase 1
- Hamartoma · Phase 1
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Phase 1
- Leukemia, Myeloid, Acute · Phase 2
- Leukemia, Myeloid, Chronic-Phase · Phase 1/Phase 2
- Myelodysplastic Syndromes · Phase 1/Phase 2
- Neoplasms · Phase 1
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 1
Mechanism of action
- Growth factor receptor-bound protein 2ANTISENSE INHIBITOR
GRB2 antisense inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- bp1001
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04196257 | Phase 1 | Feb 29, 2020 | Bio-Path Holdings, Inc. |
| NCT02923986 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2016 | Bio-Path Holdings, Inc., University of Texas at Houston |
| NCT02781883 | Phase 2 | May 1, 2016 | Bio-Path Holdings, Inc., University of Texas at Houston |
| NCT01159028 | Phase 1 | Jun 1, 2010 | Bio-Path Holdings, Inc., University of Texas at Houston |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bio-Path Holdings, Inc. | For profit | 4 | 4 | 2 | 2010 |
| University of Texas at Houston | Academic/Hospital | 3 | 0 | 2 | 2010 |
2 organizations
Page 1 / 1